title: AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotyping.
abstract: This study was undertaken to analyze the differentiation profiles assessed by immunophenotyping in AIDS-related B-cell lymphoma (ARL) and their relation to the clinical course. Paraffin-embedded sections of 89 ARL cases during 1989 to 2004 were stained immunohistochemically with antibodies to CD3, CD10, CD20, CD38, CD138/Syndecan-1 (Syn-1), multiple myeloma-1/interferon regulatory factor-4 (MUM1/IRF4), B-cell lymphoma protein-2 (BCL-2), BCL-6, latent membrane protein-1 (LMP-1), and Ki-67. Expression of CD10 and CD20 were associated with better overall survival (OS; P = .009 and P = .04, respectively). Expression of CD20 was associated with longer disease-free survival (DFS; P = .03), whereas expression of CD138/Syn-1 was associated with shorter DFS (P = .03). OS and DFS were worse in patients with immunophenotypic profiles related to post-germinal center (GC) differentiation (BCL-6 and CD10 negative, MUM1/IRF4 and/or CD138/Syn-1 positive) when compared with GC differentiation (P = .01). When controlled for age-adjusted International Prognostic Index (IPI), prior AIDS-defining illness (ADI), and year of ARL diagnosis, a post-GC differentiation remained significantly associated with poor OS and DFS. Expression of CD10 was associated with a preserved immunocompetence, whereas CD20 was less frequent in patients developing ARL while on highly active antiretroviral therapy (P = .04). In summary, lack of CD20 or CD10 expression and a post-germinal center signature are associated with a worse prognosis in ARL.
authors.affiliation: Infectious Diseases Outpatient Clinic, II. Department of Medicine, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Chemnitzstrasse 33, 24116 Kiel, Germany. c.hoffmann@med2.uni-kiel.de
authors.forename: Christian
authors.initials: C
authors.lastname: Hoffmann
authors.forename: Markus
authors.initials: M
authors.lastname: Tiemann
authors.forename: Carsten
authors.initials: C
authors.lastname: Schrader
authors.forename: Dirk
authors.initials: D
authors.lastname: Janssen
authors.forename: Eva
authors.initials: E
authors.lastname: Wolf
authors.forename: Mathias
authors.initials: M
authors.lastname: Vierbuchen
authors.forename: Reza
authors.initials: R
authors.lastname: Parwaresch
authors.forename: Karen
authors.initials: K
authors.lastname: Ernestus
authors.forename: Andreas
authors.initials: A
authors.lastname: Plettenberg
authors.forename: Albrecht
authors.initials: A
authors.lastname: Stoehr
authors.forename: Gerd
authors.initials: G
authors.lastname: Fatkenheuer
authors.forename: Christoph
authors.initials: C
authors.lastname: Wyen
authors.forename: Mark
authors.initials: M
authors.lastname: Oette
authors.forename: Heinz-August
authors.initials: HA
authors.lastname: Horst
mesh_terms: D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000096:biosynthesis* / Q000276:immunology; D018951:Antigens, CD20 / Q000096:biosynthesis / Q000276:immunology; D000943:Antigens, Differentiation / Q000096:biosynthesis* / Q000276:immunology; D014408:Biomarkers, Tumor / Q000032:analysis; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D018858:Germinal Center / Q000276:immunology; D006801:Humans; D007150:Immunohistochemistry; D016130:Immunophenotyping / Q000379:methods*; D016483:Lymphoma, AIDS-Related / Q000175:diagnosis / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D015260:Neprilysin / Q000096:biosynthesis / Q000276:immunology; D011379:Prognosis; D012044:Regression Analysis; D015203:Reproducibility of Results; D012189:Retrospective Studies; D016019:Survival Analysis; D013997:Time Factors
chemical_list: D015703:Antigens, CD; D018951:Antigens, CD20; D000943:Antigens, Differentiation; D014408:Biomarkers, Tumor; D015260:Neprilysin